Eli Lilly and Company's (LLY) Hold (C+) Rating Reaffirmed at Weiss Ratings

Key Points

• The stock of Eli Lilly and Company (LLY) was reaffirmed with a "hold (C+)" rating by Weiss Ratings, while various analysts have adjusted their price targets, with UBS lowering it to $895 and Guggenheim raising it to $948.
• Eli Lilly's recent quarterly results showed an earnings per share of $6.31, surpassing expectations, with revenue increasing by 37.6% year-over-year.
• Insider transactions included notable purchases by Director J Erik Fyrwald and CEO David A. Ricks, indicating confidence in the company's performance, as they increased their respective holdings.

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s stock had its "hold (c+)" rating reissued by stock analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Other analysts have also issued reports about the company. UBS Group dropped their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Berenberg Bank reiterated a "hold" rating and set a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Guggenheim lifted their price target on Eli Lilly and Company from $875.00 to $948.00 and gave the stock a "buy" rating in a report on Wednesday. Morgan Stanley dropped their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating on the stock in a report on Friday, October 3rd. Finally, Leerink Partnrs downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $943.00.

Eli Lilly and Company Stock Up 0.2%

Eli Lilly and Company stock traded up $1.92 during trading on Wednesday, hitting $845.55. 2,177,741 shares of the company were exchanged, compared to its average volume of 3,975,851. The business's 50 day moving average is $738.69 and its 200 day moving average is $766.57. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $937.00. The company has a market capitalization of $800.28 billion, a P/E ratio of 55.26, a PEG ratio of 1.18 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.Eli Lilly and Company's quarterly revenue was up 37.6% compared to the same quarter last year. During the same period last year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Insider Buying and Selling

In other Eli Lilly and Company news, Director J Erik Fyrwald bought 1,565 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were acquired at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares of the company's stock, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock valued at $2,894,841 in the last 90 days. Corporate insiders own 0.13% of the company's stock.

Hedge Funds Weigh In On Eli Lilly and Company

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LLY. Sheets Smith Investment Management purchased a new position in shares of Eli Lilly and Company in the 3rd quarter worth about $908,000. New Capital Management LP boosted its holdings in shares of Eli Lilly and Company by 14.0% in the 3rd quarter. New Capital Management LP now owns 326 shares of the company's stock worth $249,000 after purchasing an additional 40 shares in the last quarter. Talbot Financial LLC boosted its holdings in shares of Eli Lilly and Company by 34.1% in the 3rd quarter. Talbot Financial LLC now owns 36,334 shares of the company's stock worth $27,723,000 after purchasing an additional 9,247 shares in the last quarter. Marshall Financial Group LLC boosted its holdings in shares of Eli Lilly and Company by 2.3% in the 3rd quarter. Marshall Financial Group LLC now owns 3,057 shares of the company's stock worth $2,333,000 after purchasing an additional 69 shares in the last quarter. Finally, FCG Investment Co boosted its holdings in shares of Eli Lilly and Company by 3.5% in the 3rd quarter. FCG Investment Co now owns 2,645 shares of the company's stock worth $2,018,000 after purchasing an additional 90 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.